SCHEMBL722305

SCHEMBL722305

COc1cccc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4C)c3o2)c1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 10/20 0.43
PRKCD Q05655 10/20 0.43
LYN P07948 3/20 0.43
JAK2 O60674 1/20 0.40
JAK3 P52333 1/20 0.40
ADRA2A P08913 1/20 0.38
ADRA2C P18825 1/20 0.38
ADRA1D P25100 1/20 0.38
ADRA1A P35348 1/20 0.38
ADRA1B P35368 1/20 0.38
RET P07949 1/20 0.37
GAK O14976 2/20 0.37
RIPK2 O43353 2/20 0.37
COQ8A Q8NI60 2/20 0.37
NLK Q9UBE8 2/20 0.37
BRAF P15056 2/20 0.36
RAF1 P04049 1/20 0.36
LCK P06239 2/20 0.36
P2RX7 Q99572 1/20 0.36
MAPK14 Q16539 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL723994 0.92 PRKCQ (0.43) PRKCQPRKCDLYNJAK2JAK3
SCHEMBL725080 0.86 JAK2 (0.45) PRKCQPRKCDJAK2JAK3GAK
SCHEMBL723540 0.84 PRKCQ (0.37) PRKCQPRKCDLYNJAK2JAK3
SCHEMBL725010 0.83 PRKCQ (0.50) PRKCQPRKCDLYNJAK2JAK3
SCHEMBL10268104 0.82 PRKCQ (0.51) PRKCQPRKCDJAK2JAK3BRAF
SCHEMBL721499 0.82 PRKCQ (0.43) PRKCQPRKCDLYNJAK2JAK3
SCHEMBL10267539 0.81 PRKCQ (0.47) PRKCQPRKCDLYNADRA2AADRA2C
SCHEMBL723524 0.80 PRKCQ (0.44) PRKCQPRKCDLYNLCKP2RX7
SCHEMBL723399 0.80 PRKCQ (0.40) PRKCQPRKCDLYNLCKP2RX7
SCHEMBL721627 0.78 MAPKAPK2 (0.40) PRKCQPRKCDLYNADRA2AADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
CN-103052640-A Furopyridine derivatives MERCK PATENT GMBH 2013-04-17 CN claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB PRKCQ 662/4885PRKCD 964/4885LYN 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.